Viewing Study NCT05733650

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:10 PM
Ignite Modification Date: 2026-05-29 @ 4:22 PM
Study NCT ID: NCT05733650
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2023-05-25
First Post: 2023-01-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Expanded Access Program for Epcoritamab
Sponsor: Genmab
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Large B-cell Lymphoma View
None Diffuse Large B-Cell Lymphoma, Not Otherwise Specified View
None Primary Mediastinal Large B-cell Lymphoma (PMBCL) View
None High Grade B-cell Lymphoma (HGBCL) View
None Grade 3B Follicular Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Epcoritamab View
None GEN3013 View
None Diffuse large B-cell lymphoma View
None Lymphoma View
None DuoBody-CD3xCD20 View
None Bispecific antibody View
None Early access View
None Double-hit DLBCL View
None Triple-hit DLBCL View
None Follicular grade 3b View
None Transformed DLBCL View
None High-grade B-cell lymphoma View
None Primary mediastinal large B-cell lymphoma (PMBCL) View